# CBA-1535

Source: https://onco.cc/drugs/cba-1535/  
OnCo record `cba-1535` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

CBA-1535 is an experimental trispecific T cell engager from Chiome Bioscience, in phase 1 trials for advanced solid tumours, malignant mesothelioma and small cell lung cancer and other cancers.

## Summary

CBA-1535 (Tb535H) is a trispecific T cell engager (Tribody) from Chiome Bioscience. A trispecific Tribody T-cell engager with binding sites for 5T4, CD3 and 5T4; it recruits the patient's T cells and directs them to attack tumours expressing 5T4. Its furthest stage is phase 1, for advanced solid tumours, malignant mesothelioma, small cell lung cancer and non-small cell lung cancer. ClinicalTrials.gov registers it in one study linked below. Phase 1 NCT07016997 recruiting per ClinicalTrials.gov, including a combination part with pembrolizumab. Whether it works in people has not been established unless a trial below reports it.

## Fields

- Kind: Treatment
- Status: phase-1
- Last checked: 2026-11-03
- Also known as: Tb535H
- Tags: pipeline; ctgov-ingest
- Code: CBA-1535
- Modality: Trispecific T cell engager (Tribody)
- Mechanism: A trispecific Tribody T-cell engager with binding sites for 5T4, CD3 and 5T4; it recruits the patient's T cells and directs them to attack tumours expressing 5T4.

## Sources

- Chiome Bioscience: chiome.co.jp: https://www.chiome.co.jp/en/pipeline/
- Chiome Bioscience: chiome.co.jp: https://www.chiome.co.jp/en/pipeline/
- Chiome Bioscience: clinicaltrials.gov: https://clinicaltrials.gov/api/v2/studies/NCT07016997
- ClinicalTrials.gov: trials of CBA-1535: https://clinicaltrials.gov/search?intr=CBA-1535

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- targets: [CD3](https://onco.cc/targets/cd3/)
- companies: [Chiome Bioscience](https://onco.cc/companies/chiome-bioscience/)
- trials: [A Phase I, First in Human Study of CBA-1535, T Cell Engager(5T4/CD3/5T4) in Patients With Advanced Solid Tumors.](https://onco.cc/trials/nct07016997/)

---
JSON: https://onco.cc/api/v1/entities/cba-1535.json